Facebook Pixel Two to six, where is the fix? | Chronicle Pharmabiz - health - Lees dit verhaal op Magzter.com

Poging GOUD - Vrij

Two to six, where is the fix?

Chronicle Pharmabiz

|

July 24, 2025

THERE is a debate going on in the circle of highly qualified pharmacists, especially among the pharmacy teachers, that, what should be the minimum duration of pharmacist course. This is intensified after the Pharmacy Council of India announced its decision of splitting B. Pharm course into B. Pharm Industrial and B. Pharm Clinical courses. But there are lot of voices for and few against the proposal. Some even suggesting entirely a new course. Let us discuss the pros and cons of all those views in brief.

- Prof. S. Balasubramanian

Two years pharmacist course

The people for it are conservatives or self-centered who do not want to disturb existing [for more than half a Century!] 2 years D. Pharm course. They are obviously not for the upgradation of the profession, as it may affect their business and profit! Resisting all move to upgrade the course with all their might and influence for decades, these people want to maintain status co. Now knowingly or unknowingly National Education Policy [NEP] also promotes their interest and PCI has announced it is for continuation of D. Pharm course and those who leave the B. Pharm course abruptly in the middle [after 2 years of course!] will be given Diploma in Pharmacy as per NEP. Is it not a super idea? Will they give similar diploma for the students who leave after second year MBBS? When there can be semi-baked pharmacists, why not half cooked doctors? They will make an excellent pair married to serve and save humanity! PCI which has announced earlier, its intension to abolish D. Pharm is now back tracking, simply to please their masters in the government by showing they have faithfully implemented NEP. It is more important than upgrading the profession, you know! It may be apt to quote here a para from my earlier article “Boot is on the other leg, come forward PCI” published in Pharmabiz dated 9.12.2020. “If a country is progressing means, it should upgrade its professional services by a diploma to degree to post graduate to doctoral to post-doctoral professional. Instead, we will retain all these level professional means where is the logic? Look at the developed countries, in pharmacy profession, they have moved from one year diploma to 6 years Pharm. D or M. Pharm [and stopping all short-term courses]. That is progress! Just to justify its action of prolonging D. Pharm, PCI is hiding behind NEP, we believe.” Remember it was written almost 5 years back!

Three years course

MEER VERHALEN VAN Chronicle Pharmabiz

Chronicle Pharmabiz

Devices sector raises concern over notification proposing fee for tests

THE medical devices industry has raised concern over the Department of Health and Family Welfares' draft notification introducing fee for test or evaluation of medical devices and mandating inclusion of licence number of sub contractor on the product labels. The Department published the draft notification on April 10, proposing various amendments to the Medical Devices Rules (MDR), 2017 including introduction of fee for test or evaluation of 11 types of tests or evaluation.

time to read

2 mins

April 30, 2026

Chronicle Pharmabiz

Panel asks DoP to take efforts to decrease imported content in medical devices

OBSERVING that a majority of the medical devices market is addressed by imports, the Parliamentary Panel on Chemicals and Fertilisers has recommended to the Department of Pharmaceuticals (DOP) to take measures including promotion of stronger collaboration among the industry, academic institutions and research organisations to accelerate indigenous development of advanced medical devices.

time to read

1 mins

April 30, 2026

Chronicle Pharmabiz

AI in endoscopy will improve detecting early-stage cancer markers

INDIA has been moving steadily towards better cancer care. However, many cancers in India are still detected late, especially those in the digestive system.

time to read

2 mins

April 30, 2026

Chronicle Pharmabiz

Telangana appoints DG of DCA as compounding authority

IN a significant move to streamline regulatory compliance under the newly enacted Jan Vishwas provisions, the Government of Telangana has officially designated the Director General (DG) of the state’s Drugs Control Administration (DCA), Shahnawas Quasim, as the 'Compounding Authority'.

time to read

2 mins

April 30, 2026

Chronicle Pharmabiz

AIOCD seeks PM's intervention against e-pharmacies

THE All India Organisation of Chemists & Druggists (AIOCD), representing over 12.40 lakh pharmacists and distributors, has formally petitioned Prime Minister Narendra Modi to intervene against the unregulated growth of e-pharmacies and predatory pricing by large corporate entities.

time to read

1 mins

April 30, 2026

Chronicle Pharmabiz

Shed The Cavalier Attitude

A Parliamentary Panel has recently asked the Department of Pharmaceuticals (DoP) to take corrective steps to remove any administrative and procedural delays related to the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme.

time to read

2 mins

April 30, 2026

Chronicle Pharmabiz

DCOIWA slams new DCGI recruitment rules, cites dilution of tech standards

THE Drugs Control Officers (I) Welfare Association (DCOIWA), the national body of drug regulatory officers in the country, has criticised the Union Heath Ministry's newly notified recruitment rules for the post of DCGI, labelling them as a serious policy lapse.

time to read

1 mins

April 30, 2026

Chronicle Pharmabiz

Experts highlight the need for data exclusivity to protect MSMES

EXPERTS have highlighted the need for clinical data exclusivity in order to protect MSME drug innovators in India.

time to read

2 mins

April 30, 2026

Chronicle Pharmabiz

Mid-sized hospitals in Tier-2 cities stranded in a financial vacuum: Expert

MID-sized hospitals in Tier-2 cities are currently trapped in a financial vacuum. This is because funding usually arrives either too early as venture capital or too late as a financial buyout, said Rakshith Rangarajan, equity fund manager, Inviga Investment Advisors.

time to read

2 mins

April 30, 2026

Chronicle Pharmabiz

Indian healthcare sector faces escalating cyber risks

INDIAN healthcare sector is confronting a surge in cyber threats as increasingly complex hospital IT ecosystems create multiple vulnerabilities for potential breaches.

time to read

2 mins

April 30, 2026

Listen

Translate

Share

-
+

Change font size